VIR BIOTECHNOLOGY INC reports a Return on Equity (ROE) of -54.47%.

What is VIR's dividend yield?

VIR BIOTECHNOLOGY INC offers a dividend yield of 0.00%.

What is VIR's Quality Score?

Our AI rates VIR's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy VIR?

Our AI Timing Score for VIR is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does VIR belong to?

VIR BIOTECHNOLOGY INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

VIR (NASDAQ) Stock Analysis | VIR BIOTECHNOLOGY INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

VIR AI Analysis Summary

Our AI summary for VIR: VIR BIOTECHNOLOGY INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -54.47%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

VIR

VIR BIOTECHNOLOGY INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 8.66

-0.24 (-2.70%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-54.5%

ROE

-43.2%

ROA

0.00%

Div Yield

VIR BIOTECHNOLOGY INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 8.66 Price -0.24 (-2.70%) Day Change	NEWS SCORE: 99

VIR, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	8.66
PBV / Sector	1.85 / 5.20
Earning Per Share	-2.55

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	14.58 M GREAT
Average 1W Daily Value	11.69 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-675.96 / 98.71
NPM Average (%) / Sector	-540.00 / -1,721.76
NPM Change Average (%) / Sector	-585.09 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-43.17 / 27.02
ROA Average (%) / Sector	-27.56 / -368.17
ROA Change Average (%) / Sector	-60.45 / 5,404.12
ROE (%) / Sector	-54.47 / 3.47
ROE Average (%) / Sector	-34.19 / 6.51
ROE Change Average (%) / Sector	-54.30 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:39
Symbol	VIR
Name	VIR BIOTECHNOLOGY INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	168.65 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,501.00 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1800 Owens Street, San Francisco, CA, United States, 94158

Phone: 415 906 4324

Website: https://www.vir.bio

Employees: 367

Sector: Healthcare >> Biotechnology

Description: Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.